SYSubhash Yadav

Subhash Yadav

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Subhash Yadav has a total of 133 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pancreatic schwannoma mimicking a cystic pancreatic neoplasm: A report with radiologic–pathologic correlation

    by Khushi Naik, Amitkumar Choudhari, Shraddha Patkar, Mukta Ramadwar, Subhash Yadav

    Was not provided for this article.

  • Development of a novel predictive nomogram to prevent ‘futile surgery’ in gallbladder cancers: A single center analysis of 1196 resected gallbladder cancers

    by Gurudutt P. Varty, Shraddha Patkar, Mufaddal Kazi, Karthik Velmurugan, Amita Sekhar Padhy, Baskaran Dhanapal, Sujat Lele, Snigdha Kamini, Abdeali Saif Arif Kaderi, Akash Pawar, et al.


  • Undifferentiated Carcinoma With Osteoclast-like Giant Cells of the Pancreaticobiliary Tract: A Single Tertiary-Care-Oncology Center Case Series

    by Neelam Bhandari, Subhash Yadav, Gauri Deshpande, Rajiv Kaushal, Suman Kumar Ankathi, Vikas Ostwal, Munita Bal, Kedar Deodhar, Mukta Ramadwar

    Context. Undifferentiated carcinomas with osteoclast-like giant cells of the pancreaticobiliary tract (UCOGCs) are rare but distinctive tumors with limited literature. Objective. To study the clinicopathologic characteristics of UCOGCs including morphology, immunohistochemistry (IHC), management, and survival outcomes. Design. Assessment of 12 patients of UCOGC found over 10 years from a tertiary care oncology center database. Results. The mean age at diagnosis was 54.8 years (35-69 years) with a striking men:women ratio of 1:1.5. Eleven of 12 tumors (91%) involved the pancreas, while 1 was in the gallbladder fossa (8%). The mean tumor size was 8.8 cm (range: 4.2-18 cm). Fifty-eight percent showed metastasis at presentation, most commonly to the liver (57%). On microscopy, epithelioid-predominant histology was seen in 91%; 5 of these had an additional spindle/sarcomatoid morphology, while 1 tumor showed pure sarcomatoid histology. By immunohistochemistry, keratins were expressed in the neoplastic mononuclear cells (6 of 9, 67%). In terms of management, 2 of 11 (18%) patients underwent surgery alone; 1 of 11 (9%) received neoadjuvant chemoradiation, followed by surgery and adjuvant chemotherapy; 2 of 11 (18%) underwent surgery, followed by adjuvant chemotherapy; 4 of 11 (36%) received chemotherapy alone; and 2 of 11 (18%) received palliative care. On follow-up, 9 of 12 patients succumbed within a year of diagnosis (75%). The 6-month overall survival (OS) was 44%, and the mean survival period was 5 months (range: 8 days-1 year). Conclusions. UCOGCs are rare, aggressive variants of carcinoma and ought to be classified separately. Owing to their unique etiopathogenetic mechanisms, further exploration and large studies are required to devise newer, more effective therapeutic regimes.

  • Aberrant Expression of Pneumocytic Markers (TTF-1 and Napsin-A) in Biliary Duct and Gallbladder Adenocarcinomas; A Potential Diagnostic Pitfall

    by Rutvij Khedkar, Radhika Agrawal, Subhash Yadav, Rajiv Kumar Kaushal

    Cholangiocarcinomas and gallbladder carcinomas are epithelial tumours with biliary differentiation. On histology and immunohistochemistry, they resemble adenocarcinomas and possess overlapping immunohistochemical profiles. Diagnosing these tumours is best done using appropriate imaging and clinical features with compatible immunohistochemistry. Immuno-staining for thyroid transcription factor-1 (TTF-1) and novel aspartic proteinase of pepsin A (Napsin-A) is believed to be specific for primary pulmonary adenocarcinomas. We herein report uncommon instances of strong and diffuse expression of these markers in two examples of adenocarcinomas arising from the bile duct and gallbladder. A review of the literature and a summary of similar studies relating to aberrant TTF-1 and Napsin-A expression in biliary tract adenocarcinomas are presented.


  • Performance of Low-Dose Immunotherapy and Standard-Dose Immunotherapy in Microsatellite Instability-High Metastatic Colorectal Cancer: Real-World Data (CLouD—High Study)

    by Mehak Trikha, Laboni Sarkar, Aditya Dhanawat, Noorzia Syed, Himanshu Gujarathi, Manan Vora, A. Sree Sivakumar Raja, Prabhat Bhargava, Anant Ramaswamy, Sarika Mandavkar, et al.

    PURPOSE: Standard-dose immune checkpoint inhibitors (SD-ICIs) are the standard of care as initial therapy in microsatellite instable-high (MSI-H) advanced/metastatic colorectal adenocarcinomas (mCRC), but there are preclinical data to suggest that low-dose ICIs (LD-ICI) might also have similar efficacy. MATERIALS AND METHODS: A retrospective study of patients with MSI-H mCRC receiving ICIs between June 2017 and January 2023 was conducted. The primary end point of the study was 12-month progression-free survival (PFS), which was computed using the Kaplan-Meier method. RESULTS: A total of 65 patients were available for analysis during the study period. Sixty patients (92%) received nivolumab, whereas the remaining received pembrolizumab. First-line ICIs were received by 18 patients (28%), whereas 47 patients (72%) received ICIs during later lines. Thirty patients (47%) received LD-ICIs (all received nivolumab), with the remaining receiving SD-ICIs (53%). At a median follow-up of 16.5 (95% CI, 11.8 to 21.2) months, median PFS was not reached in the entire cohort. The 12-month PFS rate in the LD-ICI cohort was 90%, whereas it was 75.8% in the SD-ICI cohort. There were no statistical differences in patients receiving ICIs as first-line therapy (12 months PFS—94.4%) or during later lines of therapy (12-month PFS—77.9%; P = .56). CONCLUSION: ICIs in the current study show survivals which are similar to those seen in seminal trials in patients with MSI-H mCRC. Low-dose ICIs appear to work in MSI-H mCRC and should be explored prospectively in clinical trials. Patients with MSI-H status should be exposed to ICIs, whether initially or later during treatment, whenever feasible.


  • Trastuzumab Plus Gemcitabine-Cisplatin for Treatment-Naïve Human Epidermal Growth Factor Receptor 2–Positive Biliary Tract Adenocarcinoma: A Multicenter, Open-Label, Phase II Study (TAB)

    by Vikas Ostwal, Sarika Mandavkar, Prabhat Bhargava, Sujay Srinivas, Akhil Kapoor, Omshree Shetty, Sadhana Kannan, Deepali Chaugule, Rajshree Patil, Manali Parulekar, et al.

    PURPOSE: Human epidermal growth factor receptor 2 (HER2) overexpression is seen in 4%-16% of biliary tract cancers (BTCs). We aimed to evaluate the clinical activity of gemcitabine-cisplatin (GC) plus anti-HER2 antibody trastuzumab as initial treatment in HER2-positive BTCs. METHODS: This study was an investigator-initiated, open-label, single-arm, multi-institutional, phase II trial in adult patients with HER2-positive (defined as immunohistochemistry [IHC] 3+ or IHC 2+ and fluorescent in situ hybridization–positive), treatment-naïve BTCs. The primary end point of the study was 6-month progression-free survival (PFS). Next-generation sequencing was performed on tissue samples to evaluate mutational status. RESULTS: From March 2020 to August 2022, of the 876 screened patients, 118 (13.4%) were found to have HER2-positive status, of whom 90 were enrolled in the study. Most patients had GBC (n = 96; 96%) with two or more sites of metastatic disease (n = 70; 78%). With a median follow-up of 17.3 (95% CI, 15.22 to 19.32) months, 72 patients had disease progression with a median PFS of 7 (95% CI, 6.2 to 7.8) months. The diagnosis to event 6-month PFS rate was 75.6% (95% CI, 66.6 to 84.6). A complete or partial response was seen in 50 (55.5%) patients and 22 (24.4%) patients had stable disease as the best response to treatment, for an overall disease control rate of 80%. The presence of isolated TP53 mutations was associated with inferior PFS compared with other mutations (TERT promoter, HER2, PIK3CA, etc) or no detected mutations (6.51 v 12.02 v 10.58 months; P < .001). CONCLUSION: The combination of GC and trastuzumab achieved its primary end point of improving PFS compared with historical data in the treatment-naïve HER2-positive BTC. Evaluating additional mutations such as TP53 and PIK3CA along with HER2 testing may help to preferentially select patients for anti-HER2 therapy in the future (Clinical Trial Registry India number: CTRI/2019/11/021955).


  • Open Access

    Colorectal Carcinoma metastasizing to Scrotum: A series of five cases with unusual presentation and late recurrences from a single tertiary oncology centre of India

    by Disha Bilala, Subhash Yadav, Suman Kumar Ankathi, Rajiv Kaushal, Gauri Deshpande, Munita Bal, Kedar Deodhar, Santosh Menon, Mukta Ramadwar

    Background Colorectal carcinoma (CRC) is a common malignancy, frequently metastasizing to the liver, lungs, and regional lymph nodes. However, metastasis to the scrotum is exceedingly rare, with few cases reported in the literature. In this study, we present a series of five cases of colorectal carcinoma metastasizing to the scrotum, emphasizing their unusual clinical presentation and late recurrences. Methods We did a retrospective review of 7 years from 2015–2022 for cases of scrotal metastasis in cases of CRC. Results The means age in our study was 38 years (22–61 years) and the median time interval between the primary diagnosis and scrotal metastasis was 31.6 months (0-104 months). Case presentations included scrotal swelling initially misdiagnosed as a hydrocele (case 1), non-healing cutaneous ulcers (cases 3 and 5), a scrotal skin papilloma (case 4), and a cutaneous nodule (case 2). Conclusion This series of five cases highlights the rarity and diagnostic challenges associated with colorectal carcinoma metastasizing to the scrotum. The extended latency between primary tumor diagnosis and scrotal metastasis, coupled with atypical clinical presentations, underscores the importance of maintaining a high index of suspicion. Clinicians should be vigilant, especially when evaluating patients with a history of colorectal carcinoma, to promptly identify such uncommon metastatic sites.

  • Open Access

    Intratumoural metastasis of primary lung adenocarcinoma to non-invasive follicular thyroid neoplasm with papillary-like nuclear features

    by Subhash Yadav, Suman Kumar Ankathi, Asawari Patil, Rajiv Kaushal

    Metastasis to the thyroid gland is very uncommon with an incidence of 2-3% of all thyroid malignancies. A higher incidence is noted in autopsy studies indicating incidental detec- tion. However, tumour-to-tumour metastasis is extremely uncommon with a handful of cases published in the literature to date. Also, non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFT-P) is a rare neoplasm; diagnosis requires meticulous sampling of the entire capsule and fulfilment of other diagnostic criteria. We report a case of primary adenocarcinoma of lung in a 57-year-old female who additionally had a left thyroid nodule which appeared suspicious on ultrasonography. Histology of lung tumour was conventional papillary adenocarcinoma while aspiration cytology from the thyroid raised suspicion of metastatic adenocarcinoma. On hemithyroidectomy, the thyroid nodule showed metastatic adenocarcinoma in the centre of the nodule, while the peripheral por- tion showed non-invasive follicular thyroid neoplasm with papillary-like nuclear features; the diagnosis of which was confirmed with complete sampling of the thyroid capsule. The immunoprofile also supported the above dual histology. This is an extremely uncommon occurrence and metastasis within a NIFT-P has not been reported to the best of our knowl- edge.


  • Open Access

    Imaging Recommendations for Diagnosis, Staging, and Management of Peritoneal Malignancies

    by Amit Kumar Choudhari, Anuradha Chandramohan, Nitin Shetty, Suyash Kulkarni, Shailesh Shrikhande, Avanish Saklani, Rohin Mittal, Kedar Deodhar, Subhash Yadav, Reena Engineer, et al.

    Peritoneum is a serosal membrane lining the solid viscera and the hollow viscus of the abdomen and is made of a single layer of mesothelial cells. The most common primaries that spread to the peritoneum include gastrointestinal, ovarian, colorectal, and peritoneal metastases can be seen at some point during the disease course in 15 to 43%, 60 to 70% and 15 to 20% of patients, respectively. Other malignancies involving the peritoneum such as primary peritoneal carcinoma, peritoneal mesothelioma, peritoneal lymphomatosis, pseudomyxoma peritonei from low-grade appendiceal mucinous neoplasm, are far less common. The review strives to provide a framework for diagnosis and management of the disease.

  • Top Cited Papers

    Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study

    by Vijay Maruti Patil, Vanita Noronha, Nandini Menon, Rahul Rai, Atanu Bhattacharjee, Ajay Singh, Kavita Nawale, Shweta Jogdhankar, Rupali Tambe, Sachin Dhumal, et al.

    PURPOSE: The regimens approved for the treatment of advanced head and neck squamous cell carcinoma are accessible to only 1%-3% of patients in low- and middle-income countries because of their cost. In our previous study, metronomic chemotherapy improved survival in this setting. Retrospective data suggest that a low dose of nivolumab may be efficacious. Hence, we aimed to assess whether the addition of low-dose nivolumab to triple metronomic chemotherapy (TMC) improved overall survival (OS). METHODS: This was a randomized phase III superiority study. Adult patients with recurrent or newly diagnosed advanced head and neck squamous cell carcinoma being treated with palliative intent with an Eastern Cooperative Oncology Group performance status of 0-1 were eligible. Patients were randomly assigned 1:1 to TMC consisting of oral methotrexate 9 mg/m2 once a week, celecoxib 200 mg twice daily, and erlotinib 150 mg once daily, or TMC with intravenous nivolumab (TMC-I) 20 mg flat dose once every 3 weeks. The primary end point was 1-year OS. RESULTS: One hundred fifty-one patients were randomly assigned, 75 in TMC and 76 in the TMC-I arm. The addition of low-dose nivolumab led to an improvement in the 1-year OS from 16.3% (95% CI, 8.0 to 27.4) to 43.4% (95% CI, 30.8 to 55.3; hazard ratio, 0.545; 95% CI, 0.362 to 0.820; P = .0036). The median OS in TMC and TMC-I arms was 6.7 months (95% CI, 5.8 to 8.1) and 10.1 months (95% CI, 7.4 to 12.6), respectively ( P = .0052). The rate of grade 3 and above adverse events was 50% and 46.1% in TMC and TMC-I arms, respectively ( P = .744). CONCLUSION: To our knowledge, this is the first-ever randomized study to demonstrate that the addition of low-dose nivolumab to metronomic chemotherapy improved OS and is an alternative standard of care for those who cannot access full-dose checkpoint inhibitors.